Such therapeutic strategies, if validated in further studies and clinical trials, could offer new avenues for improving the management of breast cancer, particularly in cases where CD147-mediated pathway activation contributes to disease aggressiveness and resistance to standard treatments. This evidence concerns the gene BSG and breast carcinoma.